NATICK, Mass.–(BUSINESS WIRE)–AffyImmune Therapeutics, Inc., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today that it will present an abstract in a poster session at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10, 2024, in San Diego, California. Presented findings will highlight research applying the affinity-tuned, trackable, ICAM-1 targeting CAR T cell therapy AIC100 to additional solid tumor types where there is significant unmet medical need.
Details of the poster presentation are as follows:
Poster Title: AIC100 CAR-T cells targeting ICAM-1 are efficacious against solid tumors in xenograft mouse models of Non-Small Cell Lung Cancer (NSCLC) and Cervical Cancer (CC).
Date and Time: Tuesday Apr 9, 2024, 9:00 AM – 12:30 PM
Presenting Author: Alyssa Birt, AffyImmune Therapeutics
Session Category: Immunology
Session Title: Adoptive Cell Therapies 3: CAR-T Cells
Location: Poster Section 2, Poster Board Number: 16
Published Abstract Number: 4007
About AffyImmune Therapeutics
AffyImmune is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR-T cell therapies to transform the lives of patients with cancer. The Company’s proprietary technology utilizing ICAM1/LFA-1 interaction can potentially address all critical CAR-T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion, while also allowing in vivo tracking of the CAR-T cells. Its lead candidate, AIC100, is a ICAM1-directed CAR-T therapy being developed for patients with advanced thyroid cancer. AffyImmune is developing a focused pipeline of therapeutics targeting ICAM-1 in oncologic indications with high unmet medical need. AffyImmune is based in Natick, MA. For more information, visit www.affyimmune.com.
Contacts
Media
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744
